A randomised controlled trial to assess the antiplatelet effect of a 600mg (single-dose) and 1,200mg (split-dose) loading dose of clopidogrel and the impact of verapamil, a potent CYP3A4 inhibitor, on the incidence of clopidogrel resistance defined by the VerifyNow (Accumetrics Ltd) P2Y12 platelet function analyzer in patients with coronary disease.

Trial Profile

A randomised controlled trial to assess the antiplatelet effect of a 600mg (single-dose) and 1,200mg (split-dose) loading dose of clopidogrel and the impact of verapamil, a potent CYP3A4 inhibitor, on the incidence of clopidogrel resistance defined by the VerifyNow (Accumetrics Ltd) P2Y12 platelet function analyzer in patients with coronary disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2016

At a glance

  • Drugs Clopidogrel (Primary) ; Verapamil
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Therapeutic Use
  • Acronyms PRINC
  • Most Recent Events

    • 22 Jun 2016 Results published in the Journal of the American College of Cardiology
    • 03 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top